Next Treatments
Back to Eczema

benralizumab

Sold as Fasenra for other conditions

TypeInjection StageStopped · Phase 2 Why it stoppedDidn't work well enough · AstraZeneca · Sep 13, 2022“The study did not meet the primary endpoint.” (NCT04605094) Latest updateAug 22, 2025Phase 2 results posted
Picture from the US label: NDC 0310-1830-30 Rx only FASENRA PEN™ (benralizumab) Injection For Subcutaneous Injection Only Store the FASENRA PEN refrigerated at 36°F…
From the labelA picture from the US label, as DailyMed publishes it.

What stands out

New approach in eczema

  • Binds to IL-5 receptor, part of the docking point for IL-5, a signal that helps immune cells called eosinophils survive
  • Injection every 4 weeks in trials
Derived from US label · NCT03563066 · UniProt Q01344 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT04605094
Stopped earlyThe study did not meet the primary endpoint.From the trial’s registry record
NCT04605094 · Ages 12+ · This is a summary of trial data for informational purposes only. It is not medical advice.
All 2 benralizumab trials
PostedTrialPhaseAgesPeople
Aug 2025NCT03563066Phase 218–6520
Jun 2023NCT04605094 Stopped earlyPhase 212+194

History

Earliest recorded event: Nov 14, 2017. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • May 13, 2026New use approvedFDA approved a new use or patient group (efficacy supplement 23). FDA approval letter
  • Aug 22, 2025Phase 2 results postedEffect of Benralizumab in Atopic Dermatitis ClinicalTrials.gov NCT03563066
  • Sep 17, 2024New use approvedFDA approved a new use or patient group (efficacy supplement 21). FDA approval letter
  • Apr 5, 2024New use approvedFDA approved a new use or patient group (efficacy supplement 20). FDA approval letter
  • Jun 27, 2023Phase 2 results posted · Trial stopped earlyEfficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Why it stopped: The study did not meet the primary endpoint. ClinicalTrials.gov NCT04605094
  • Sep 13, 2022Trial stopped earlyReason: The study did not meet the primary endpoint. ClinicalTrials.gov NCT04605094
  • Apr 25, 2022Phase 2 main data collected · Trial stopped earlyEfficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Why it stopped: The study did not meet the primary endpoint. ClinicalTrials.gov NCT04605094
  • Sep 28, 2021Phase 2 trial completedEffect of Benralizumab in Atopic Dermatitis ClinicalTrials.gov NCT03563066
  • Oct 3, 2019New use approvedFDA approved a new use or patient group (efficacy supplement 5). FDA approval letter
  • Sep 4, 2018Phase 2 trial startedEffect of Benralizumab in Atopic Dermatitis ClinicalTrials.gov NCT03563066
  • Nov 14, 2017First FDA approvalFirst FDA approval of the drug (not for eczema). FDA approval letter

Sources

From the FDA
Trials
For patients